Table 1.
Variable | Ruxolitinib (N = 71) |
---|---|
Median (range) age, y | 58 (18-73) |
Age group, n (%) | |
<65 y | 58 (81.7) |
≥65 y | 13 (18.3) |
Female, n (%) | 36 (50.7) |
Race, n (%) | |
White | 66 (93.0) |
Black | 3 (4.2) |
Asian | 2 (2.8) |
MAGIC aGVHD grade, n (%) | |
II | 23 (32.4) |
III | 34 (47.9) |
IV | 14 (19.7) |
Steroid-refractory criteria, n (%) | |
Progressive GVHD after 3 d of primary treatment | 19 (26.8) |
GVHD not improved after 7 d of primary treatment | 30 (42.3) |
Previously began CS therapy at a lower dose, but developed new GVHD in another organ system | 8 (11.3) |
Unable to tolerate CS taper | 14 (19.7) |
Median (range) prior exposure to corticosteroids, d | 15 (3-285) |
Underlying malignancy, n (%) | |
Acute myeloid leukemia | 20 (28.2) |
Myelodysplastic syndrome | 20 (28.2) |
Lymphoma | 9 (12.7) |
Acute lymphoblastic leukemia | 8 (11.3) |
Chronic lymphocytic leukemia | 3 (4.2) |
Myelofibrosis/myeloproliferative neoplasm | 2 (2.8) |
Multiple myeloma | 2 (2.8) |
Other | 7 (9.9) |
Donor type, n (%) | |
Matched unrelated donor | 27 (38.0) |
Matched related donor | 18 (25.4) |
Mismatched related donor | 11 (15.5) |
Mismatched unrelated donor | 10 (14.1) |
Other | 5 (7.0) |
Conditioning regimen, n (%) | |
Nonmyeloablative | 36 (50.7) |
Myeloablative | 31 (43.7) |
Missing | 4 (5.6) |
Prior lines of therapy (other than corticosteroids), n (%) | |
1 | 59 (83.1) |
>1 | 12 (16.9) |
Graft type, n (%) | |
Peripheral blood stem cells | 57 (80.3) |
Bone marrow | 13 (18.3) |
Umbilical cord blood | 1 (1.4) |
CMV serostatus, n (%)* | |
Donor-positive/recipient-positive | 24 (33.8) |
Donor-positive/recipient-negative | 7 (9.9) |
Donor-negative/recipient-positive | 16 (22.5) |
Donor-negative/recipient-negative | 23 (32.4) |
Missing | 1 (1.4) |
CS, corticosteroid.
Donor serostatus was missing from 1 patient (patient was positive).